A study that was recently published in the Journal Neurobiology of Aging showed the results of a series of oxygen therapy tests conducted on genetically engineered mice. The study was conducted by a team of researchers at the University of Tel Aviv, and revealed that the mice, which were genetically altered to develop features of Alzheimer’s disease, expressed substantial reductions in their symptoms after receiving hyperbaric oxygen therapy (HBOT) daily for 2 weeks. This hyperbaric oxygen therapy is designed in a way where a person will enter a pressurized chamber, and once they are ready will begin to inhale oxygen that is set at a higher pressure than normal. This will, increase the amount of oxygen that is being delivered to the blood, a, which, in turn, will improve blood is delivering to other parts of the body. Hyperbaric Oxygen Therapy has been approved by the FAD and has been used in the treatment of several medical conditions like the “bends” as well as burns and carbon monoxide poisoning. However, it is noted in the study that, although the chamber has been used to treat other neurological conditions, it has not been tested on Alzheimer’s disease specifically before this study. The results showed that the mice improved scores in behavioural test and expressed several biochemical signs of cognition improvement, like reduced brain inflammation.
AUTHOR(S): Catharine Paddock
DATE RETRIEVED: Friday December 8th, 2017